New Drug for Chronic Migraine: FDA Approves Atogepant to Prevent Chronic Migraine in Adults

In the Press release published by AbbVie on April 17, 2023, it was reported that the FDA approved the expansion of the indication of atogepant (Qulipta, AbbVie) for the preventive treatment of migraine in adults. After this event, atogepant was introduced with the first and only oral calcitonin gene-related peptide (CGRP) receptor antagonist approved to prevent episodic and chronic migraine.

Atogepant was approved in September 2021 as a preventive treatment for episodic migraine. Atogepant is available as a single daily dose for the preventive treatment of episodic migraine: 10, 30, and 60 mg. Only 60 mg of the drug is indicated for the preventive treatment of chronic migraine. It can be taken with or without food. The most common side effects of Atogepant include constipation, nausea, and tiredness/drowsiness.

FDA Approves Spinal Cord Stimulation (SCS) System for Diabetic Peripheral Neuropathy

On January 26, 2023, it was announced that the FDA (US Food and Drug Administration) had approved Abbott’s Proclaim XR spinal cord stimulation (SCS) system for treating painful diabetic peripheral neuropathy.

Approved in 2019 for the treatment of chronic pain, the Proclaim XR SCS system provides stimulation at low doses and has been shown to relieve pain in patients with diabetic peripheral neuropathy.

After a successful trial period applied with a minimally invasive method, patients are implanted with the Proclaim XR SCS system. Patients will have the ability to control their treatment via an Apple device. People receiving treatment from the Proclaim XR SCS system can communicate with the doctor using the NeuroSphere Virtual Clinic, an application of Abbott, and their treatment can be adjusted remotely. The Proclaim XR SCS system battery can operate for up to 10 years at low dose settings.

Dr. Tural Bayramov, MD Speaks About the Management of Taste and Smell Disorders After COVID-19 at the 17th National Pain Congress in Turkey.

The 17th National Pain Congress in Turkey was held in Antalya on 04-07 May this year. One of the interesting speeches at the congress was given by Dr. Tural Bayramov, MD. In his presentation titled, “Is Stellate Ganglion Block effective in the treatment of smell and taste disorders in Long COVID cases?”, pain medicine specialist Dr. Tural Bayramov talked about his own experiences. Dr. Bayramov demonstrated the positive results of the Stellate Ganglion Block, which he applied to patients with taste and smell sensory disorders after Covid-19. His patients had previously received different treatments, including smell therapy, but had no benefit.

The condition known as Long COVID is when you have actually recovered from the Covid-19 disease but still have some symptoms of this infection for a long time. In particular, there are many symptoms such as weakness, insomnia, difficulty concentrating, and so on. Smell and taste disorders, which are among the most important findings among these findings, reduce the quality of life of the patients. These patients receive different treatments for months and many do not benefit from these treatments.

“We observed the positive results of the ultrasound-guided stellate ganglion block in Long Covid cases who applied to our clinic with taste and smell disorders. It had positive effects not only on the sense of taste and smell but also on some other findings we encountered in Long COVID cases,” said Dr. Tural Bayramov

A New Guide for Fibromyalgia Patients: Dr. Tural Bayramov’s Book Now Available on Amazon!

Fibromyalgia is a disease that causes symptoms such as chronic pain, fatigue, and tenderness, and it affects millions of people around the world. To make the lives of those living with fibromyalgia easier, a new book “Fibromyalgia: A Patient’s Guide to Understanding, Coping, and Finding Hope” written in English by pain doctor Tural Bayramov, MD has been released. The book is designed to support people struggling with fibromyalgia and improve their quality of life.

The book offers a comprehensive guide on how to manage fibromyalgia symptoms and treatment options. Fibromyalgia patients as well as healthcare professionals can benefit from the book. While reading the book, readers can get the necessary information about fibromyalgia and its management without getting lost in scientific terminology.

To access the book, please click on the link: Fibromyalgia: A Patient’s Guide to Understanding, Coping, and Finding Hope